A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
NCT00974584
Completed
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of oral (PO) GDC-0941 administered with one of three planned regimens: Arm A: paclitaxel and carboplatin in bevacizumab-ineligible NSCLC patients, Arm B: paclitaxel, carboplatin, and bevacizumab in bevacizumab-eligible NSCLC patients and Arm C: pemetrexed, cisplatin, and bevacizumab in bevacizumab-eligible, non-squamous NSCLC patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Buffalo, New York +2 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)
NCT01366131
Completed
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of MEGF0444A combined with paclitaxel + carboplatin + bevacizumab therapy in patients with histologically or cytologically documented inoperable, locally advanced, metastatic (Stage IV), or recurrent non-squamous NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Birmingham, Alabama +41 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors
NCT01301716
Completed
This is an open-label, multicenter, Phase Ib dose-escalation study to assess the safety, tolerability, and pharmacokinetics of GDC-0980 administered with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin to patients with locally advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Los Angeles, California +4 locations
Conditions: Solid Cancers
Register for Updates
A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01075464
Completed
This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Not set, Scottsdale, Arizona +4 locations
Conditions: Solid Cancers
Register for Updates
A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer
NCT00352690
Terminated
This study is intended to evaluate the role of paclitaxel poliglumex and carboplatin in the treatment of unresectable Stage III non-small cell lung cancer along with radiation therapy in a multi-institutional trial. Consolidation chemotherapy with paclitaxel poliglumex and carboplatin will follow the completion of chemoradiation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/27/2016
Locations: University of California, San Francisco, San Francisco, California +7 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Study of Weekly LOC-paclitaxel Injection for Melanoma
NCT01039844
Terminated
The goal of this clinical research study is to find the highest tolerable dose of LOC-paclitaxel when given to patients with metastatic melanoma. The safety of this drug and if it can control the disease is also being studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2016
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma
Register for Updates
Lenalidomide and Paclitaxel in Prostate Cancer
NCT00933426
Terminated
The goal of the Phase I part of this clinical research study is to find the highest tolerable dose of Revlimid® (lenalidomide) that can be given in combination with paclitaxel to patients with prostate cancer who have failed treatment with taxanes. The goal of the Phase II part of this clinical research study is to learn if lenalidomide and paclitaxel can help to control prostate cancer. The safety of this combination treatment will be studied in both phases of the study. UPDATE: Study was t... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/25/2016
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
NCT01497470
Completed
The primary goal of this study is to determine if custirsen has an effect on the way the body distributes and gets rid of paclitaxel, the standard administered chemotherapy. The study will also evaluate if custirsen influences the way the body distributes and gets rid of carboplatin (another standard administered chemotherapy) and will measure custirsen blood levels in this cancer population. Finally, the study will evaluate the safety and tolerability of adding custirsen to the standard paclita... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2016
Locations: Teva Investigational Site 002, Detroit, Michigan +3 locations
Conditions: Cancer
Register for Updates
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
NCT00874848
Completed
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with cetuximab and concomitant paclitaxel and carboplatin therapy in patients with previously untreated advanced NSCLC. Additionally, this study will provide guidance for the design of more definitive efficacy studies of Imprime PGG in NSCLC patients.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/06/2016
Locations: Medical College of Georgia, Augusta, Georgia +13 locations
Conditions: NSCLC
Register for Updates
Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
NCT00003899
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of melphalan and thiotepa plus bone marrow or peripheral stem cell transplantation in treating patients who have recurrent or refractory solid tumors.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/03/2016
Locations: Fred Hutchinson Cancer Research Center, Seattle, Washington
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Register for Updates
A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
NCT02033551
Completed
This is an extension study to evaluate the safety of Veliparib monotherapy or in combination with Carboplatin plus Paclitaxel or modified Folinic Acid/Fluorouracil/Irinotecan (FOLFIRI) in subjects with solid tumors.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/26/2016
Locations: Site Reference ID/Investigator# 117416, Scottsdale, Arizona +4 locations
Conditions: Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer, Gastric Cancer, Solid Tumors
Register for Updates
Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.
NCT00524303
Completed
This study will examine safety and efficacy of Lapatinib in combination with a standard neoadjuvant chemotherapy including 5FU, Epirubicin, Cyclophosphamide and Paclitaxel. Tumor tissue will be obtained at 3 timepoints (optional 4th) to evaluate tumor response to treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/23/2016
Locations: GSK Investigational Site, Fountain Valley, California +22 locations
Conditions: Neoplasms, Breast
Register for Updates